投稿ビュー
Sangamo Presents T Cell Engineering Capabilities at Immuno-Oncology Summit - Markets Insider
Sangamo Presents T Cell Engineering Capabilities at Immuno-Oncology Summit Markets Insider RICHMOND, Calif., Aug. 31, 2017 /PRNewswire/ -- Sangamo Therapeutics (Nasdaq: SGMO) this afternoon is presenting preclinical data demonstrating the Company's engineering capabilities in T cell genome editing using zinc finger nucleases (ZFNs). |
投稿情報
評価
おすすめ
タグ
転職
"
"@type":
"@type":"NewsArticle"
"Auga Group"
"C" grade Nevada infrastructure
"Errol Oh"
"Jane Goodyear"
"Optimistically Cautious"
"a man and his prostate"
"akcijų pardavimas"
"analytics:simplereach:id":"54
"author":"Art Berman"
"author":"Brad McMillan"
"author":"Bryan Rich"
"author":"Christopher Helman"
"author":"Claire Poole"
"author":"Clare O'Connor"
"author":"David Blackmon"